BioNTech SE Sponsored ADR (BNTX) shares soared 5.8% in the last trading session to close at $105. The move was backed by solid volume with far more shares changing hands than in a normal session.

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The company’s shares opened today at $121.40. According to ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock ...

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC). The vaccine is claimed to use the ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

(RTTNews) - Kuick Research announced the initiation of the first mRNA lung cancer vaccine trials globally with German biotech firm BioNTech SE's (BNTX) BNT116 as a significant breakthrough in ...

The FDA has authorized the use of new vaccines from Pfizer/BioNTech and Moderna which have been designed to defend against the Omicron KP.2 variant of SARS-CoV-2. The nod comes as word of a new ...

If this EUA application is authorised, children 6 months to under 5 years of age would receive a primary series consisting of two 3-µg doses of the original Pfizer/BioNTech COVID-19 Vaccine ...

Along the way, Duality has entered into deals with BioNTech, BeiGene and Adcendo that could be worth more than $4 billion. Duality plans to take two bispecific ADCs and one autoimmune ADC into ...

The recent decision by partner BioNTech (BNTX) to give up on co-development of acasunlimab may also be considered as bad news, but if the candidate delivers good data in a pivotal trial ...

Healthcare & Pharmaceuticalscategory US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug June 17, 2024 Reuters, the news and media division of Thomson Reuters, ...

A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease. Janusz Racz, 67, had six syringes of the jab, each containing genetic ...